Albert Lowe
Stock Analyst at Craig-Hallum
(3.27)
# 2,475
Out of 5,133 analysts
147
Total ratings
37.9%
Success rate
4.5%
Average return
Main Sectors:
Stocks Rated by Albert Lowe
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| PVLA Palvella Therapeutics | Reiterated: Buy | $205 → $230 | $152.48 | +50.84% | 7 | Nov 6, 2026 | |
| RZLT Rezolute | Reiterated: Buy | $7 → $10 | $3.66 | +173.60% | 17 | Nov 6, 2026 | |
| IRLA IRulya Therapeutics | Reiterated: Buy | $68 | $39.80 | +70.85% | 1 | Sep 30, 2026 | |
| SPRB Spruce Biosciences | Reiterated: Buy | $140 | $43.31 | +223.25% | 4 | Sep 30, 2026 | |
| CMPX Compass Therapeutics | Reiterated: Buy | $8 | $0.7738 | +933.86% | 7 | Sep 23, 2026 | |
| CRDF Cardiff Oncology | Reiterated: Hold | n/a | $0.7261 | - | 14 | Sep 15, 2026 | |
| LCTX Lineage Cell Therapeutics | Reiterated: Buy | n/a | $0.9146 | - | 8 | Jul 14, 2026 | |
| IRD Opus Genetics | Reiterated: Buy | n/a | $3.98 | - | 11 | Jul 6, 2026 | |
| SABS SAB Biotherapeutics | Reiterated: Buy | $6 | $2.96 | +102.70% | 10 | Jun 16, 2026 | |
| NGNE Neurogene | Reiterated: Buy | $65 | $23.93 | +171.63% | 7 | May 15, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $25 → $12 | $0.2853 | +4,106.10% | 9 | May 12, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $19.86 | $11.65 | +70.51% | 12 | May 5, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | n/a | $5.53 | - | 1 | Apr 2, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | n/a | $1.09 | - | 16 | Mar 11, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $10 | $1.96 | +410.20% | 7 | Feb 12, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | n/a | $2.12 | - | 6 | Jan 23, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | n/a | $12.90 | - | 1 | Jan 12, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $4 | $1.27 | n/a | 7 | Nov 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | n/a | $6.06 | n/a | 1 | Jun 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $14 | $218.15 | n/a | 1 | Jun 4, 2024 |
Palvella Therapeutics
Nov 6, 2026
Reiterated: Buy
Price Target: $205 → $230
Current: $152.48
Upside: +50.84%
Rezolute
Nov 6, 2026
Reiterated: Buy
Price Target: $7 → $10
Current: $3.66
Upside: +173.60%
IRulya Therapeutics
Sep 30, 2026
Reiterated: Buy
Price Target: $68
Current: $39.80
Upside: +70.85%
Spruce Biosciences
Sep 30, 2026
Reiterated: Buy
Price Target: $140
Current: $43.31
Upside: +223.25%
Compass Therapeutics
Sep 23, 2026
Reiterated: Buy
Price Target: $8
Current: $0.7738
Upside: +933.86%
Cardiff Oncology
Sep 15, 2026
Reiterated: Hold
Price Target: n/a
Current: $0.7261
Upside: -
Lineage Cell Therapeutics
Jul 14, 2026
Reiterated: Buy
Price Target: n/a
Current: $0.9146
Upside: -
Opus Genetics
Jul 6, 2026
Reiterated: Buy
Price Target: n/a
Current: $3.98
Upside: -
SAB Biotherapeutics
Jun 16, 2026
Reiterated: Buy
Price Target: $6
Current: $2.96
Upside: +102.70%
Neurogene
May 15, 2026
Reiterated: Buy
Price Target: $65
Current: $23.93
Upside: +171.63%
May 12, 2026
Reiterated: Buy
Price Target: $25 → $12
Current: $0.2853
Upside: +4,106.10%
May 5, 2026
Reiterated: Buy
Price Target: $19.86
Current: $11.65
Upside: +70.51%
Apr 2, 2026
Reiterated: Buy
Price Target: n/a
Current: $5.53
Upside: -
Mar 11, 2026
Reiterated: Hold
Price Target: n/a
Current: $1.09
Upside: -
Feb 12, 2026
Reiterated: Buy
Price Target: $10
Current: $1.96
Upside: +410.20%
Jan 23, 2026
Reiterated: Buy
Price Target: n/a
Current: $2.12
Upside: -
Jan 12, 2026
Reiterated: Buy
Price Target: n/a
Current: $12.90
Upside: -
Nov 13, 2025
Reiterated: Buy
Price Target: $4
Current: $1.27
Upside: n/a
Jun 6, 2024
Reiterated: Buy
Price Target: n/a
Current: $6.06
Upside: n/a
Jun 4, 2024
Initiated Coverage: Buy
Price Target: $14
Current: $218.15
Upside: n/a